Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ziftomenib by Kura Oncology for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Ziftomenib is under clinical development by Kura Oncology and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
Ziftomenib by Kura Oncology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Ziftomenib is under clinical development by Kura Oncology and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Ziftomenib by Kura Oncology for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Ziftomenib is under clinical development by Kura Oncology and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Ziftomenib by Kura Oncology for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Ziftomenib is under clinical development by Kura Oncology and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...